Hemodynamic Significance of Periprocedural Myocardial Injury Assessed With N-Terminal Pro-B-Type Natriuretic Peptide After Percutaneous Coronary Intervention in Patients With Stable and Unstable Coronary Artery Disease (from the JUMBO-TIMI 26 Trial)

American Journal of Cardiology

Volumn 99, Issue 3, 2007, Pages 344-348

  Bonaca, Marc P ^a   Wiviott, Stephen D ^a   Sabatine, Marc S ^a   Buros, Jacqueline ^a   Murphy, Sabina A ^a   Scirica, Benjamin M ^a   Rifai, Nader ^b   Antman, Elliott M ^a   Morrow, David A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CLOPIDOGREL; CREATINE KINASE MB; PRASUGREL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART MUSCLE INJURY; HEMODYNAMIC MONITORING; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PEPTIDE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STRESS;

ADOLESCENT; ADULT; AGED; ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN PRECURSORS; RISK FACTORS; SURVIVAL RATE; VENTRICULAR FUNCTION;

EID: 33846442057     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.08.035     Document Type: Article

References (15)

1. de Lemos J.A., Morrow D.A., Bentley J.H., Omland T., Sabatine M.S., McCabe C.H., Hall C., Cannon C.P., and Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (2001) 1014-1021
2. Jernberg T., Stridsberg M., Venge P., and Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 40 (2002) 437-445
3. Morrow D.A., de Lemos J.A., Sabatine M.S., Murphy S.A., Demopoulos L., DiBattiste P., McCabe C., Gibson C.M., Cannon C.P., and Braunwald E. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST elevation MI: BNP and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 41 (2003) 1264-1272
4. Wiviott S.D., Antman E.M., Winters K.J., Weerakkody G., Murphy S.A., Behounek B.D., Carney R.J., Lazam C., McKay R.G., McCabe C.H., and Braunwald E. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111 (2005) 3366-3373
5. Kragelund C., Gronning B., Kober L., Hildebrandt P., and Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352 (2005) 666-675
6. Chew D.P., Bhatt D.L., Lincoff A.M., Wolski K., and Topol E.J. Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk. Heart 92 (2006) 945-950
7. Ellis S.G., Chew D., Chan A., Whitlow P.L., Schneider J.P., and Topol E.J. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 106 (2002) 1205-1210
8. Kini A.S., Lee P., Marmur J.D., Agarwal A., Duffy M.E., Kim M.C., and Sharma S.K. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol 93 (2004) 18-23
9. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., Jacobs A.K., Kern M.J., King III S.B., Morrison D.A., O'Neil W.W., Schaff H.V., Whitlow P.L., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2006) e166-e286
10. Bhatt D.L., and Topol E.J. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005?. Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation 112 (2005) 906-923
11. Bertinchant J.P., Polge A., Ledermann B., Genet L., Fabbro-Peray P., Raczka F., Brunet J., Poirey S., Wittenberg O., Pernel I., and Nigond J. Relation of minor cardiac troponin I elevation to late cardiac events after uncomplicated elective successful percutaneous transluminal coronary angioplasty for angina pectoris. Am J Cardiol 84 (1999) 51-57
12. Cantor W.J., Newby L.K., Christenson R.H., Tuttle R.H., Hasselblad V., Armstrong P.W., Moliterno D.J., Califf R.M., Topol E.J., and Ohman E.M. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol 39 (2002) 1738-1744
13. Selvanayagam J.B., Porto I., Channon K., Petersen S.E., Francis J.M., Neubauer S., and Banning A.P. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation 111 (2005) 1027-1032
14. Kowey P.R., Verrier R.L., Lown B., and Handin R.I. Influence of intracoronary platelet aggregation on ventricular electrical properties during partial coronary artery stenosis. Am J Cardiol 51 (1983) 596-602
15. Grund F., Sommerschild H.T., Lyberg T., Kirkeboen K.A., and Ilebekk A. Microembolization in pigs: effects on coronary blood flow and myocardial ischemic tolerance. Am J Physiol 277 (1999) H533-H542